Actively Recruiting
Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome
Led by Liu yong · Updated on 2025-12-17
766
Participants Needed
7
Research Sites
133 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter, open-label, parallel-group, randomized trial to determine if intensive lipid-lowering therapy (goal for LDL-C \<1.0 mmol/L and ≥50% reduction frome baseline) could delay progression of coronary atherosclerotic obstructive leisions compared with guideline recommended lipid-lowering therapy (goal for LDL-C \<1.8 mmol/L and ≥50% reduction frome baseline) among participants between 18-60 years old with non-invasively managed chronic coronary syndrome (at least one lesion with a 50%-70% stenosis).
CONDITIONS
Official Title
Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 60 years at screening
- Stable angina symptoms with suspected or confirmed coronary artery disease
- Coronary CT angiography showing at least one major coronary artery (diameter 651.5 mm) with at least one lesion causing 50%-70% stenosis
- Using statin therapy alone for at least 4 weeks prior to enrollment with baseline LDL-C 651.8 mmol/L or not on lipid-lowering therapy with baseline LDL-C 652.6 mmol/L
You will not qualify if you...
- Left main coronary artery disease or severe three-vessel disease
- Ultra-high-risk ASCVD defined as 652 severe ASCVD events or 1 severe event with 652 high-risk factors
- Use of PCSK9 inhibitors or ezetimibe within 8 weeks prior to enrollment
- Baseline LDL-C 652.6 mmol/L if on statins or 654.9 mmol/L if not on statins
- Familial hypercholesterolemia
- Known allergy or intolerance to lipid-lowering drugs used in the trial
- Severe congestive heart failure, liver or kidney dysfunction, or malignancy
- Pregnant or breastfeeding female patients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400015
Not Yet Recruiting
2
The Ninth Clinical Medical College of Guangzhou University of Chinese Medicine
Dongguan, Guangdong, China, 523000
Not Yet Recruiting
3
The Third Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510000
Not Yet Recruiting
4
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China, 510100
Actively Recruiting
5
The Eighth Affiliated Hospital of Sun Yat-sen University
Shenzhen, Guangdong, China, 518033
Not Yet Recruiting
6
Zhongshan People's Hospital
Zhongshan, Guangdong, China, 528400
Not Yet Recruiting
7
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China, 116000
Not Yet Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here